DCPH News and Press, Deciphera Pharmaceuticals Inc.

2024-06-11 10:22:44 ET More on Deciphera Pharmaceuticals Diving Into Deciphera Pharmaceuticals Deciphera Pharmaceuticals ticks higher as HSR waiting period for ONO sale expires ONO to acquire Deciphera Pharmaceuticals in $2.4B deal Seeking Alpha’s Quan...

– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...

2024-05-22 13:50:44 ET More on Deciphera Pharmaceuticals Diving Into Deciphera Pharmaceuticals ONO to acquire Deciphera Pharmaceuticals in $2.4B deal Deciphera stock soars after Ono Pharmaceutical’s $2.4B buyout deal Seeking Alpha’s Quant Rating...

2024-05-10 13:54:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ: DCPH ) just reported results for the first quarter of 2024. Deciphera Pharmaceuticals reported earnings per share of -52 cents. This was...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-05 06:27:47 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

2024-05-03 15:00:00 ET More on the markets My Current View Of The Market: May 2024 Edition (Technical Analysis) SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish 'Sell in May and go away': Does it apply in 2024? ...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

2024-04-30 15:03:39 ET Summary The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech sto...

NEW YORK, NY / ACCESSWIRE / April 30, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Deciphera Pharmaceuticals, Inc. (NAS...